Why did 4DMedical shares charge higher today, then drop?

Shares in 4DMedical Ltd (ASX: 4DX) jumped more than 8% in early trade after the company said a study validating its key technology had been published in a prestigious journal.

Strong endorsement

4DMedical said in a statement to the ASX that a study evaluating its technology, CT:VQ, had been published in the American Journal of Respiratory and Critical Care Medicine – the world’s leading respiratory medicine journal.

 The company went on to say:

The study included patients with severe emphysema undergoing bilateral lung volume reduction surgery (LVRS) and analysed pre‑operative non‑contrast inspiratory and expiratory CT scans using quantitative imaging techniques, including CT‑derived perfusion (CT:VQ). The authors conclude that integrating functional data from CT:VQ perfusion and anatomical (emphysema) information from routine CT imaging can enhance and streamline patient selection for LVRS, increasing successful outcomes from 48% to 76%, with potential to reduce reliance on additional perfusion imaging studies and improve clinical outcomes.

4DMedical said its technology was designed to integrate into routine radiology workflows and “can analyse historical CT scans, enabling functional assessment earlier in the care pathway, including during LVR patient selection discussions”.

The company added:

LVRS is a specialised surgical intervention typically performed at advanced medical centres (AMCs). Efficient identification of suitable candidates is critical, as outcomes are strongly influenced by underlying lung physiology, including the distribution of emphysema and regional perfusion. By improving pre‑operative selection, functional CT‑based assessment has the potential to reduce unnecessary invasive procedures and optimise utilisation of high‑value surgical respiratory services.

4DMedical said hospital margins from LVRS were highly sensitive to patient selection, and its technology directly enhances LVRS economics by enabling earlier, non-invasive identification of optimal candidates.

The company added:

By reducing reliance on additional imaging, avoiding low‑value surgical interventions and improving post‑operative outcomes, functional CT imaging supports higher procedural success rates, more efficient use of surgical infrastructure and improved contribution margins per case, reinforcing LVRS as a precision‑led, high‑value service line for advanced medical centres.

The company is also presenting the data at the ATS International Conference 2026 in Orlando, Florida, which is being held this week.

Shares fluctuating

While 4DMedical shares have retraced from highs around $6.80 in mid-April, shareholders in the company are still sitting on gains of more than 1000% for the past 12 months.

The shares traded as high as $4.35 early on Tuesday, up 8.7%, before sliding to be 1.8% lower at $3.93, with 3.2 million shares traded.

The company is valued at $2.38 billion.

The post Why did 4DMedical shares charge higher today, then drop? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Why this ASX 200 rocket stock is crashing again today
• Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.